• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five Forces Summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Application o Market segments o Comparison by Application placement o Therapeutics - Market size and forecast 2019-2024 o Diagnostics - Market size and forecast 2019-2024 o Market opportunity by Application • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Volume driver - Demand led growth o Volume driver - Supply led growth o Volume driver - External factors o Volume driver - Demand shift in adjacent markets o Price driver - Inflation o Price driver - Shift from lower to higher priced units o Market challenges o Market trends • Vendor Landscape o Overview o Vendor landscape o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o 4D pharma Plc o ENTEROME SA o Evelo Biosciences Inc. o Ferring International Center SA o Osel Inc. o Second Genome Inc. o Seres Therapeutics Inc. o Synlogic Inc. o Synthetic Biologics Inc. o Vedanta Biosciences Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations • Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 4 • 5.Key Finding 5 • 6.Key Finding 6 • 7.Key Finding 7 • 8.Market in focus • 9.Parent market • 10.Market characteristics • 11.Product / Service portfolio of key vendors included in the market definition • 12.Market segments • 13.Global - Market size and forecast 2019 - 2024 ($ million) • 14.Global market: Year-over-year growth 2019 - 2024 (%) • 15.Five forces analysis 2019 & 2024 • 16.Bargaining power of buyers • 17.Bargaining power of suppliers • 18.Threat of new entrants • 19.Threat of substitutes • 20.Threat of rivalry • 21.Market condition - Five forces 2019 • 22.Application placement - Market share 2019-2024 (%) • 23.Comparison by Application placement • 24.Therapeutics - Market size and forecast 2019-2024 ($ million) • 25.Therapeutics - Year-over-year growth 2019-2024 (%) • 26.Diagnostics - Market size and forecast 2019-2024 ($ million) • 27.Diagnostics - Year-over-year growth 2019-2024 (%) • 28. Market opportunity by Application • 29.Customer landscape • 30.Market share by geography 2019-2024 (%) • 31.Geographic comparison • 32.North America - Market size and forecast 2019-2024 ($ million) • 33.North America - Year-over-year growth 2019-2024 (%) • 34.Europe - Market size and forecast 2019-2024 ($ million) • 35.Europe - Year-over-year growth 2019-2024 (%) • 36.Asia - Market size and forecast 2019-2024 ($ million) • 37.Asia - Year-over-year growth 2019-2024 (%) • 38.ROW - Market size and forecast 2019-2024 ($ million) • 39.ROW - Year-over-year growth 2019-2024 (%) • 40.Key leading countries • 41.Market opportunity by geography ($ million) • 42.Impact of drivers • 43.Impact of challenges • 44.Landscape disruption • 45.Industry risks • 46.Vendors covered • 47.Market positioning of vendors • 48.4D pharma Plc - Overview (1/3) • 49.4D pharma Plc - Overview (2/3) • 50.4D pharma Plc - Overview (3/3) • 51.4D pharma Plc - Business segments • 52.4D pharma Plc - Key offerings • 53.4D pharma Plc - Key customers • 54.4D pharma Plc - Segment focus • 55.ENTEROME SA - Overview (1/3) • 56.ENTEROME SA - Overview (2/3) • 57.ENTEROME SA - Overview (3/3) • 58.ENTEROME SA - Product and service • 59.ENTEROME SA - Key offerings • 60.ENTEROME SA - Key customers • 61.ENTEROME SA - Segment focus • 62.Evelo Biosciences Inc. - Overview (1/3) • 63.Evelo Biosciences Inc. - Overview (2/3) • 64.Evelo Biosciences Inc. - Overview (3/3) • 65.Evelo Biosciences Inc. - Business segments • 66.Evelo Biosciences Inc. - Key offerings • 67.Evelo Biosciences Inc. - Key customers • 68.Evelo Biosciences Inc. - Segment focus • 69.Ferring International Center SA - Overview (1/3) • 70.Ferring International Center SA - Overview (2/3) • 71.Ferring International Center SA - Overview (3/3) • 72.Ferring International Center SA - Product and service • 73.Ferring International Center SA - Key offerings • 74.Ferring International Center SA - Key customers • 75.Ferring International Center SA - Segment focus • 76.Osel Inc. - Overview (1/3) • 77.Osel Inc. - Overview (2/3) • 78.Osel Inc. - Overview (3/3) • 79.Osel Inc. - Product and service • 80.Osel Inc. - Key offerings • 81.Osel Inc. - Key customers • 82.Osel Inc. - Segment focus • 83.Second Genome Inc. - Overview (1/3) • 84.Second Genome Inc. - Overview (2/3) • 85.Second Genome Inc. - Overview (3/3) • 86.Second Genome Inc. - Product and service • 87.Second Genome Inc. - Key offerings • 88.Second Genome Inc. - Key customers • 89.Second Genome Inc. - Segment focus • 90.Seres Therapeutics Inc. - Overview (1/3) • 91.Seres Therapeutics Inc. - Overview (2/3) • 92.Seres Therapeutics Inc. - Overview (3/3) • 93.Seres Therapeutics Inc. - Business segments • 94.Seres Therapeutics Inc. - Key offerings • 95.Seres Therapeutics Inc. - Key customers • 96.Seres Therapeutics Inc. - Segment focus • 97.Synlogic Inc. - Overview (1/3) • 98.Synlogic Inc. - Overview (2/3) • 99.Synlogic Inc. - Overview (3/3) • 100.Synlogic Inc. - Business segments • 101.Synlogic Inc. - Key offerings • 102.Synlogic Inc. - Key customers • 103.Synlogic Inc. - Segment focus • 104.Synthetic Biologics Inc. - Overview (1/3) • 105.Synthetic Biologics Inc. - Overview (2/3) • 106.Synthetic Biologics Inc. - Overview (3/3) • 107.Synthetic Biologics Inc. - Product and service • 108.Synthetic Biologics Inc. - Key offerings • 109.Synthetic Biologics Inc. - Key customers • 110.Synthetic Biologics Inc. - Segment focus • 111.Vedanta Biosciences Inc. - Overview (1/3) • 112.Vedanta Biosciences Inc. - Overview (2/3) • 113.Vedanta Biosciences Inc. - Overview (3/3) • 114.Vedanta Biosciences Inc. - Product and service • 115.Vedanta Biosciences Inc. - Key offerings • 116.Vedanta Biosciences Inc. - Key customers • 117.Vedanta Biosciences Inc. - Segment focus • 118.Currency conversion rates for US$ • 119.Research Methodology • 120.Validation techniques employed for market sizing • 121.Information sources • 122.List of abbreviations

4D pharma Plc,ENTEROME SA,Evelo Biosciences Inc.,Ferring International Center SA,Osel Inc.,Second Genome Inc.,Seres Therapeutics Inc.,Synlogic Inc.,Synthetic Biologics Inc.,Vedanta Biosciences Inc.